Altimmune's Weight Loss Drug Shows Promising Results in Minimizing Muscle Loss
In a significant development, Altimmune's experimental drug, pemvidutide, has demonstrated the ability to minimize muscle mass loss during weight loss, potentially setting it apart from competitors.
- Altimmune announced that its experimental weight loss drug, pemvidutide, minimized muscle mass loss in a phase-2 trial, with patients losing an average of 16% of their body weight.
- The drug's weight loss results are comparable to those achieved through diet and exercise, with 75% of the weight loss coming from fat and only 25% from lean mass.
- The preservation of lean mass is considered critical to avoiding negative outcomes such as sarcopenia and bone fractures, especially in older adults and women.
- Altimmune is also developing pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a common form of liver disease.
- The pharmaceutical industry is witnessing a surge in the development of weight loss drugs, with several companies, including Novo Nordisk and Eli Lilly, competing in the space.
CNBC 
Forbes 
